SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: Poor Man -, buythebuy
Search This Board:
Last Post: 12/9/2016 11:02:48 AM - Followers: 188 - Board type: Free - Posts Today: 1


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Statement of Ownership (sc 13g) 12/06/2016 04:41:26 PM
USRM News: Quarterly Report (10-q) 11/08/2016 04:07:42 PM
USRM News: Statement of Ownership (sc 13g) 09/29/2016 02:37:33 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:08:00 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:05:49 PM
#18129  Sticky Note USRM 2nd "EYE DAMAGE" LAWSUIT info, WOW !! Hornet Driver 11/30/16 12:03:52 PM
#18086  Sticky Note USRM LATEST PR buythebuy 11/17/16 03:50:02 AM
#18175   Sell off? EquityElite 12/09/16 11:02:48 AM
#18174   21st Century Cures Act sent to President for Rizzler 12/08/16 10:20:16 AM
#18173   When will the gas run out? EquityElite 12/08/16 02:12:29 AM
#18172   SCcCCCCCCCCCCCaaMmmmm InvestorStemCell 12/07/16 11:39:36 PM
#18171   Quote, "THIS DILUTION IS JUST STUNNING. I DON'T Hornet Driver 12/07/16 11:34:19 PM
#18170   New SEC 13G filed...MASSIVE MORE DILUTION Poor Man - 12/07/16 11:19:37 PM
#18169   Source: mind1 12/07/16 01:42:38 PM
#18168   Do not know why they say that-- final mind1 12/07/16 01:25:26 PM
#18167   Passed.... Rizzler 12/07/16 01:16:41 PM
#18164   Quote LOL, "USRM is thin and should be Hornet Driver 12/06/16 06:32:26 PM
#18163   USRM is thin and should be trading around buythebuy 12/06/16 06:09:50 PM
#18162   New SEC 13G filed...MASSIVE MORE DILUTION Hornet Driver 12/06/16 06:00:21 PM
#18161   Agreed! Super thin i will run really hard$$ slickinvest 12/06/16 06:00:10 PM
#18160   This stock is setting up nicely. Go USRM! buythebuy 12/06/16 05:40:28 PM
#18159   Hasn't passed yet, they are now discussing the mind1 12/06/16 04:05:43 PM
#18158   US Sentate passes 21st Century Cures Act Rizzler 12/06/16 03:55:17 PM
#18157   Quote LOL, "How is it "up" when the NoMoDo 12/06/16 11:29:39 AM
#18156   No bid? EquityElite 12/06/16 11:05:48 AM
#18153   Quote LOL, " Nice volume today and up 20%." Hornet Driver 12/06/16 10:47:33 AM
#18152   Nice volume today and up 20%. NoMoDo 12/06/16 10:34:46 AM
#18151   Quote LOL, "Wow, Pre Market buy of $2.5MM Hornet Driver 12/06/16 10:18:39 AM
#18150   That was a sell off too? EquityElite 12/06/16 10:05:54 AM
#18149   Wow, Pre Market buy of $2.5MM shares. Rizzler 12/06/16 09:57:02 AM
#18148   US Senate to Vote today on 21st Century Rizzler 12/06/16 09:49:46 AM
#18147   WeeeeeeeeeAAAAAAAAeeeeeeeeee slickinvest 12/01/16 07:03:47 PM
#18146   SccccccccAAAAAAAAAAmmmmmmm InvestorStemCell 12/01/16 06:40:30 PM
#18145   Level 2 looks beauty slickinvest 12/01/16 03:13:23 PM
#18144   Lawsuit? EquityElite 12/01/16 12:22:53 PM
#18143   Very obvious USRM will be going into bankruptcy mind1 12/01/16 10:18:53 AM
#18142   Quote LOL, "Where do you see large insider buying?" Hornet Driver 12/01/16 10:12:25 AM
#18141   21st Century Cures Act passed by House! Burn Rizzler 12/01/16 07:36:12 AM
#18140   21st Century Cures Act passed!!!!! White House on Rizzler 12/01/16 07:35:22 AM
#18139   Stem Cell accelerated approval path included in 21st Rizzler 12/01/16 07:32:49 AM
#18138   Where do you see large insider buying? Last mind1 12/01/16 07:16:32 AM
#18137   The float is very appealing, and it doesn't buythebuy 12/01/16 04:30:38 AM
#18136   Looks like a lot of Insider Buying, Big SamLBInj 12/01/16 01:11:15 AM
#18135   Dilution? EquityElite 11/30/16 08:28:24 PM
#18133   21st Century Cures Act aka REGROW ACT Rizzler 11/30/16 03:45:02 PM
#18132   Incredibly Serious Allegations Poor Man - 11/30/16 03:07:25 PM
#18131   Poor Man- Hornet Driver 11/30/16 01:01:03 PM
#18130   Wow is Right! Poor Man - 11/30/16 12:40:50 PM
#18129   USRM 2nd "EYE DAMAGE" LAWSUIT info, WOW !! Hornet Driver 11/30/16 12:03:52 PM
#18127   Weeeeeeew$$$ slickinvest 11/30/16 09:01:23 AM
#18126   ScAAAAAAAAAAAam InvestorStemCell 11/30/16 08:51:23 AM
#18125   $6 BUCK TRADE moves it "up" 32%, LOL !!! Hornet Driver 11/29/16 10:50:36 AM
#18124   3.4 MILLION shares SOLD pre-market ???? Hornet Driver 11/29/16 09:36:46 AM
#18123   Has this company gone bankrupt? Tourbillon7575 11/29/16 04:42:35 AM
#18121   Calm before the.... calm? EquityElite 11/28/16 06:25:42 PM
#18120   Almost 2.5 hours...ZERO VOLUME..?? Hornet Driver 11/28/16 12:01:52 PM
#18119   The ole ZERO VOLUME opener...??? Hornet Driver 11/28/16 10:54:25 AM